NCT04654390View on ClinicalTrials.gov

The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

December 17, 2021

Study Completion Date

December 17, 2021

Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
DRUG

DWP16001 Amg

Tablets, Orally, Once daily

Trial Locations (1)

Unknown

The Catholic University of Korea Bucheon St. Mary's Hospital, Republic of Korea, Bucheon-si

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT04654390 - The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter